Cell Source, Inc.
CLCS · OTC
12/31/2024 | 9/30/2024 | 6/30/2024 | 3/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.13 | 0.37 | -0.00 | -0.25 |
| FCF Yield | -4.75% | -4.71% | -3,422.12% | -1.10% |
| EV / EBITDA | -68.53 | -25.93 | -8.49 | -22.16 |
| Quality | ||||
| ROIC | 7.85% | 9.41% | 16.33% | 15.31% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.27 | 0.45 | 0.75 | 0.14 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -17.11% | 43.10% | -545.94% | 75.93% |
| Safety | ||||
| Net Debt / EBITDA | -26.59 | -11.05 | -8.46 | -8.21 |
| Interest Coverage | -3.20 | -1.65 | -3.90 | -7.95 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |